1. Home
  2. CMMB vs RCG Comparison

CMMB vs RCG Comparison

Compare CMMB & RCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • RCG
  • Stock Information
  • Founded
  • CMMB 2004
  • RCG 1994
  • Country
  • CMMB Israel
  • RCG United States
  • Employees
  • CMMB N/A
  • RCG N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • RCG Investment Managers
  • Sector
  • CMMB Health Care
  • RCG Finance
  • Exchange
  • CMMB Nasdaq
  • RCG Nasdaq
  • Market Cap
  • CMMB 23.0M
  • RCG 18.2M
  • IPO Year
  • CMMB N/A
  • RCG N/A
  • Fundamental
  • Price
  • CMMB $1.16
  • RCG $2.65
  • Analyst Decision
  • CMMB Strong Buy
  • RCG
  • Analyst Count
  • CMMB 2
  • RCG 0
  • Target Price
  • CMMB $8.50
  • RCG N/A
  • AVG Volume (30 Days)
  • CMMB 186.3K
  • RCG 5.9K
  • Earning Date
  • CMMB 08-20-2025
  • RCG 01-01-0001
  • Dividend Yield
  • CMMB N/A
  • RCG 0.98%
  • EPS Growth
  • CMMB N/A
  • RCG N/A
  • EPS
  • CMMB N/A
  • RCG N/A
  • Revenue
  • CMMB N/A
  • RCG N/A
  • Revenue This Year
  • CMMB N/A
  • RCG N/A
  • Revenue Next Year
  • CMMB N/A
  • RCG N/A
  • P/E Ratio
  • CMMB N/A
  • RCG N/A
  • Revenue Growth
  • CMMB N/A
  • RCG N/A
  • 52 Week Low
  • CMMB $0.87
  • RCG $1.52
  • 52 Week High
  • CMMB $2.55
  • RCG $1.90
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 37.38
  • RCG 53.20
  • Support Level
  • CMMB $1.17
  • RCG $2.55
  • Resistance Level
  • CMMB $1.22
  • RCG $2.66
  • Average True Range (ATR)
  • CMMB 0.06
  • RCG 0.08
  • MACD
  • CMMB -0.01
  • RCG 0.00
  • Stochastic Oscillator
  • CMMB 37.50
  • RCG 66.67

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.

Share on Social Networks: